患有巨细胞动脉炎的葡萄糖皮质类药物治疗患者中的骨质疏松症:基于人口的队列分析
Batsheva Varda1, Arielle D Zur2, Yuval Kuntzman2
1Soroka University Medical Center, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
接受葡萄糖皮质类药物治疗的巨细胞动脉炎 (GCA) 患者患骨质疏松症的风险增加了一倍. 这凸显了在接受类固醇治疗的GCA患者骨健康的谨慎管理的必要性.
科学领域:
- 类风湿病学 类风湿病学
- 内分泌学 在内分泌学.
- 老年病的医生 老年病的医生
背景情况:
- 巨细胞动脉炎 (GCA) 是一种大血管血管炎,影响50岁以上的人.
- 葡萄糖皮质类药物是主要的GCA治疗方法,但携带诸如骨质疏松症等风险.
- 同时管理GCA和骨质疏松症是一个临床挑战.
研究的目的:
- 为了确定使用葡萄糖皮质类药物治疗的GCA患者骨质疏松症的发病率.
- 在这个患者群体中确定与GCA相关的其他并发症.
主要方法:
- 对6607名GCA患者和36,066名对照患者 (2002-2018) 的回顾性横截面分析.
- 使用后勤回归分析来评估GCA和骨质疏松症之间的独立关联,控制并发症.
主要成果:
- 骨质疏松症的患病率在GCA患者 (43%) 和对照组 (27%) (或2.06) 中显著更高.
- 在GCA患者中,高血压,高脂血症,糖尿病和缺血性心脏病的发病率增加.
- 在调整心血管疾病后,GCA仍然与骨质疏松症 (OR 2.1) 独立相关.
结论:
- 用葡萄糖皮质醇治疗的GCA独立地与更高的骨质疏松症风险有关.
- 医疗保健提供者应该主动考虑和管理GCA患者的骨质疏松症风险.
更多相关视频
05:55Author Spotlight: Developing a Rat Model for Weight-Bearing Intervention to Investigate Osteonecrosis of the Femoral Head
Published on: September 27, 2024
07:22Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes
Published on: March 7, 2025
相关概念视频
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
COPD: Management Using Bronchodilators and Corticosteroids
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Graves' Disease I: Introduction
Cushing Syndrome II: Pathophysiology
